Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled, Multi-center Phase III Clinical Trial of AK112 Versus Pembrolizumab as First-line Treatment for PD-L1-Positive Locally-Advanced or Metastatic Non-Small Cell Lung Cancer

NCT05499390 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT05499390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05499390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled, Multi-center Phase III Clinical Trial of AK112 Versus Pembrolizumab as First-line Treatment for PD-L1-Positive Locally-Advanced or Metastatic Non-Small Cell Lung Cancer
Lead sponsor
Akeso
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 9, 2022
Completion date
December 31, 2026
Enrollment
398 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small-cell lung cancer